Skip to main content

Praxis will receive an upfront payment from UCB, and if the option is exercised by UCB, would be eligible to receive an option fee and future success-based development and commercialization milestone payments, for a total of up to ~$100M, in addition to tiered royalties on net sales of any resulting products from the collaboration.

Stock up 2.3% after-hours.


Read the original article

Leave a Reply